Biogen Inc. (BIIB) is making notable advances, consistently standing among the top value stocks to buy. The firm is making significant strides in the bio-tech market, particularly in the fight against Alzheimer’s Disease. Lecanemab, marketed as
Leqembi, has been authorized for early treatment of Alzheimer’s in Great Britain, approved in Israel, launched in China and accepted for FDA review. Moreover, the drug secures UK approval with a drawback: an independent agency does not recommend reimbursement. Despite declining stock prices and setbacks, including the European rejection of the Alzheimer's drug, Biogen remains resilient with its proactive approach to financial management, lifting profit forecast and realizing cost-cutting measures. Furthermore, Biogen is aligning resources to strengthen the Alzheimer's disease franchise, thus progressing its turnaround effort. The firm’s Q2 earnings and sales have surpassed expectations, leading to a raised guidance for 2024. The firm is also innovating its pipeline, with Biogen's partnership with Ionis Pharmaceuticals presenting positive results from a phase 1/2 study for an Amyotrophic Lateral Sclerosis investigational drug. Additionally, Biogen’s Skyclarys received a positive CHMP opinion for the treatment of a rare neurodegenerative disease.
Biogen BIIB News Analytics from Fri, 15 Dec 2023 08:00:00 GMT to Sat, 05 Oct 2024 09:54:40 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
